Insulin Market Size Worth $111.21 Billion by 2028 at 10.8% CAGR Lead by Biosimilar Insulin Segment (Register 16% CAGR) Global Analysis by The Insight Partners
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: PR Newswire
NEW YORK, Aug. 8, 2022 /PRNewswire/ -- The Insight Partners published latest research study on "Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [Long Acting Insulin, Rapid Acting Insulin, Short Acting Insulin & Traditional Human Insulin, Concentrated Insulin & Combination Insulin, Biosimilar Insulin, Glucagon-like peptide-1 (GLP-1), Pen & Needle, and Others] and Geography", the global insulin market size is projected to grow from $54.61 Billion in 2021 to $111.21 Billion by 2028; it is expected to grow at a CAGR of 10.8% from 2022 to 2028.Download PDF Brochure of Insulin Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPRE00004051/Insulin Market Report Scope & Strategic Insights:Report CoverageDetailsMarket Size Value inUS$ 54.61 Billion in 2021Market Size Value byUS$ 111.21 Billion by 2028Growth rateCAGR of 10.8% from 2022 to 2028Forecast Period2022-2028Base Year2021No. of Pages
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- 12 Best Biotech Penny Stocks to Invest In [Yahoo! Finance]Yahoo! Finance
- Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancerBusiness Wire
- GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising RiseBusiness Wire
- GSK plc (NYSE: GSK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.MarketBeat
- GSK plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy [Seeking Alpha]Seeking Alpha
GSK
Sec Filings
- 4/17/24 - Form 6-K
- 4/17/24 - Form 6-K
- 4/17/24 - Form 6-K
- GSK's page on the SEC website